Agomelatine for depression: expanding the horizons?

@article{Norman2019AgomelatineFD,
  title={Agomelatine for depression: expanding the horizons?},
  author={Trevor R. Norman and James S. Olver},
  journal={Expert Opinion on Pharmacotherapy},
  year={2019},
  volume={20},
  pages={647 - 656}
}
ABSTRACT Introduction: Agomelatine is an antidepressant with unique pharmacological actions; it is both a melatonin agonist and selective serotonin antagonist. Both actions combined are necessary for antidepressant efficacy. Effects on melatonin receptors enable resynchronisation of disrupted circadian rhythms with beneficial effects on sleep patterns. Areas covered: The issue of use of an antidepressant for depression co-morbid with somatic disorders is covered by the authors. A review of the… Expand
The preclinical discovery and development of agomelatine for the treatment of depression
TLDR
There is now evidence supporting the clinical efficacy and safety profile of agomelatine in the acute-phase treatment of MDD, and findings of post-marketing research on safety, efficacy, and cost-effectiveness of the drug are examined. Expand
Serotonin 2 Receptors, Agomelatine, and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease
TLDR
This review summarizes the relationship between serotonin 2 receptors, agomelatine, and BPSD and provides a new idea for the study of the pathogenesis and treatment of B PSD. Expand
Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model
TLDR
It is hypothesize that agomelatine, an MT-1 and MT-2 receptor agonist and 5-HT2C receptor antagonist, holds promise in the combined treatment of insomnia, depression, and osteoporosis in middle-aged women during menopause. Expand
Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis
TLDR
It is shown that agomelatine may be another treatment option in patients with GAD, however, the results should be interpreted and translated into clinical practice with caution because the meta-analysis was based on limited numbers of clinical trials. Expand
Molecular Regulation of the Melatonin Biosynthesis Pathway in Unipolar and Bipolar Depression
TLDR
This study comprehensively analyzed the differences between healthy control subjects and unipolar and bipolar depression patients, including an analysis of the melatonin pathway at the level of the genes and serum biomarkers, and confirmed the immunomodulatory effect of melatonin agents in depression. Expand
Anhedonia as a central factor in depression: Neural mechanisms revealed from preclinical to clinical evidence
TLDR
The neurobiological mechanisms underlying anhedonia in MDD uncovered by preclinical and clinical research are synthesized to synthesize the translational gaps remain in reward motivation, effort, valuation, and learning. Expand
Update on the Relationship Between Depression and Neuroendocrine Metabolism
  • Wenxin Qiu, Xiaodan Cai, Chenhui Zheng, Shumin Qiu, Hanyang Ke, Yinqiong Huang
  • Medicine
  • Frontiers in Neuroscience
  • 2021
TLDR
An overview of the comorbidity of depression and metabolic diseases is provided to find a new clinical therapeutic intervention strategy to treat depression. Expand
New agents and perspectives in the pharmacological treatment of major depressive disorder
TLDR
Although it is expected that classic antidepressants will remain the cornerstone ofMDD treatment, at least for the near future, a large number of novel compounds is currently under investigation as for their efficacy in the treatment of MDD, many of which with promising results. Expand
Depression, antidepressants and fall risk: therapeutic dilemmas—a clinical review
TLDR
The aim of this clinical review was to summarize the existing knowledge on fall risk associated with antidepressant use in older adults, describe underlying mechanisms, and assist clinicians in decision-making with regard to (de-) prescribing antidepressants in older persons. Expand
Advances in the pharmacological management of non-24-h sleep-wake disorder
TLDR
The authors review the pharmacological therapies including exogenous melatonin and melatonin receptor agonists for the management of non-24 and introduce a historical report about the effects of melatonin on the phase shift and entrainment for blind individuals with the free-running circadian rhythm. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 106 REFERENCES
Agomelatine for the treatment of major depressive disorder
TLDR
It has been shown to be superior to placebo and similar to existing antidepressants, as demonstrated by short-term clinical trials and one relapse prevention trial, and the adverse effects in the liver may present a regulatory and marketing challenge. Expand
Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
TLDR
Current evidences on the role of agomelatine in disorders other than major depression are elucidated to point out a possible efficacy of such drug in the treatment of bipolar depression, anxiety disorders, alcohol dependence, migraines etc. Expand
A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
TLDR
Comparison studies showed agomelatine to be an intriguing option for depression and, potentially, for other therapeutic targets as well, compared to other antidepressant ones. Expand
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
TLDR
There is evidence of the superiority of agomelatine over placebo and selected antidepressants, but it is questionable whether the magnitude of effect size is clinically significant and sample characteristics are relevant to the general patient population with major depressive disorder. Expand
A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
TLDR
Based on this comprehensive review, agomelatine does not have clinically significant advantages compared with other antidepressant drugs, and it has certain limitations and disadvantages. Expand
Major depressive disorder, anhedonia, and agomelatine: An open-label study
TLDR
This is the first study where agomelatine was effective in the treatment of anhedonia and evidence of an early response is provided and the findings of improvements in depression scores are provided. Expand
Novel melatonin-based therapies: potential advances in the treatment of major depression
TLDR
This review highlights agomelatine, a melatonin-receptor agonist and selective serotonergic receptor subtype (ie, 5-HT(2C)) antagonist that has chronobiotic, antidepressant, and anxiolytic effects and outlines new antidepressant treatment strategies that target the circadian system. Expand
Agomelatine in the treatment of seasonal affective disorder
TLDR
The results of this study suggest that seasonal depression may be effectively and safely treated with agomelatine. Expand
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
TLDR
Agomelatine, a melatonergic antidepressant with a rapid onset of action, has been shown effective in various types of mood disorders and some studies find it superior to other common antidepressants that are in clinical use today. Expand
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
TLDR
Agomelatine (Valdoxan/Thymanax; Servier) was granted marketing authorization in 2009 for the treatment of major depression in Europe, thereby becoming the first approved antidepressant to incorporate a non-monoaminergic mechanism of action. Expand
...
1
2
3
4
5
...